WT1 and cancer: Thus, cancer immunotherapies targeting WT1 would be valuable.[4] However, the application of mRNA vaccines has been restricted because of their biological instability, large molecular weight, high intrinsic immunogenicity, and insufficient delivery in vivo.[5] Therefore, these limitations should be overcome to improve the use of mRNA vaccines.